# Fusion Pharmaceuticals Inc. (FUSN)

Source: https://www.quantisnow.com/company/FUSN
Generated: 2026-11-12T04:48:58.876Z

- Ticker: FUSN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2020
- Website: fusionpharma.com

## About

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

## Latest FUSN news and filings

- 2024-06-17 10:05 UTC [SEC Form 15-12G filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-fusion-pharmaceuticals-inc-5560478)
- 2024-06-10 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-fusion-pharmaceuticals-inc-5546869)
- 2024-06-10 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-fusion-pharmaceuticals-inc-5546866)
- 2024-06-10 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-fusion-pharmaceuticals-inc-5546860)
- 2024-06-05 12:38 UTC [SEC Form 25-NSE filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-fusion-pharmaceuticals-inc-5538361)
- 2024-06-04 21:35 UTC [SEC Form 4] [SEC Form 4 filed by Bitetti Teresa Marie](https://www.quantisnow.com/insight/sec-form-4-filed-by-bitetti-teresa-marie-5537049)
- 2024-06-04 21:31 UTC [SEC Form 4] [Gannon Steven returned 56,400 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/gannon-steven-returned-56400-shares-to-the-company-closing-all-5537027)
- 2024-06-04 21:31 UTC [SEC Form 4] [Valliant John returned 318,147 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/valliant-john-returned-318147-shares-to-the-company-closing-all-5537026)
- 2024-06-04 21:31 UTC [SEC Form 4] [SEC Form 4 filed by Cagnoni Pablo J](https://www.quantisnow.com/insight/sec-form-4-filed-by-cagnoni-pablo-j-5537025)
- 2024-06-04 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Lee Philina](https://www.quantisnow.com/insight/sec-form-4-filed-by-lee-philina-5537022)
- 2024-06-04 21:27 UTC [SEC Form 4] [Rawat Mohit returned 21,699 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/rawat-mohit-returned-21699-shares-to-the-company-closing-all-5537005)
- 2024-06-04 21:26 UTC [SEC Form 4] [Crowley John J returned 10,410 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/crowley-john-j-returned-10410-shares-to-the-company-closing-5536990)
- 2024-06-04 21:25 UTC [SEC Form 4] [SEC Form 4 filed by Meek David D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-meek-david-d-5536979)
- 2024-06-04 21:23 UTC [SEC Form 4] [SEC Form 4 filed by Bobilev Dmitri](https://www.quantisnow.com/insight/sec-form-4-filed-by-bobilev-dmitri-5536963)
- 2024-06-04 21:23 UTC [SEC Form 4] [SEC Form 4 filed by Bender Jeremy](https://www.quantisnow.com/insight/sec-form-4-filed-by-bender-jeremy-5536961)
- 2024-06-04 21:22 UTC [SEC Form 4] [SEC Form 4 filed by Duncan Barbara Gayle](https://www.quantisnow.com/insight/sec-form-4-filed-by-duncan-barbara-gayle-5536954)
- 2024-06-04 21:21 UTC [SEC Form 4] [Burak Eric returned 38,490 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/burak-eric-returned-38490-shares-to-the-company-closing-all-5536947)
- 2024-06-04 21:20 UTC [SEC Form 4] [Leamon Christopher P returned 11,957 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/leamon-christopher-p-returned-11957-shares-to-the-company-closing-5536944)
- 2024-06-04 21:17 UTC [SEC Form 4] [SEC Form 4 filed by Bergstrom Donald A](https://www.quantisnow.com/insight/sec-form-4-filed-by-bergstrom-donald-a-5536920)
- 2024-06-04 20:39 UTC [SEC Form POS AM filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-fusion-pharmaceuticals-inc-5536541)
- 2024-06-04 20:37 UTC [SEC Form POS AM filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-fusion-pharmaceuticals-inc-5536526)
- 2024-06-04 20:35 UTC [SEC Form POS AM filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-fusion-pharmaceuticals-inc-5536509)
- 2024-06-04 20:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-fusion-pharmaceuticals-inc-5536483)
- 2024-06-04 20:31 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-fusion-pharmaceuticals-inc-5536465)
- 2024-06-04 20:29 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-fusion-pharmaceuticals-inc-5536387)
- 2024-06-04 20:27 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-fusion-pharmaceuticals-inc-5536339)
- 2024-06-04 20:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-fusion-pharmaceuticals-inc-5536327)
- 2024-06-04 20:18 UTC [SEC Form 8-K] [Fusion Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Control of Registrant, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders](https://www.quantisnow.com/insight/fusion-pharmaceuticals-inc-filed-sec-form-8-k-changes-in-control-5536214)
- 2024-06-04 20:05 UTC [Acquisition of Fusion Pharmaceuticals Completed](https://www.quantisnow.com/insight/acquisition-of-fusion-pharmaceuticals-completed-5535859)
- 2024-05-31 20:12 UTC [SEC Form 8-K] [SEC Form 8-K filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-fusion-pharmaceuticals-inc-5529498)
- 2024-05-31 20:08 UTC [Market Chatter] [Fusion Pharmaceuticals Obtains Final Court Approval For Acquisition By AstraZeneca Subsidiary; Shareholders To Receive $21/Share Plus $3 Contingent Value Right](https://www.quantisnow.com/insight/fusion-pharmaceuticals-obtains-final-court-approval-for-acquisition-by-astrazeneca-5529428)
- 2024-05-31 20:05 UTC [Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement](https://www.quantisnow.com/insight/fusion-pharmaceuticals-receives-final-court-order-approving-arrangement-5529319)
- 2024-05-29 20:34 UTC [SEC Form 8-K] [SEC Form 8-K filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-fusion-pharmaceuticals-inc-5523521)
- 2024-05-29 20:10 UTC [Market Chatter] [Fusion Pharmaceuticals Shareholders Approve Acquisition By AstraZeneca](https://www.quantisnow.com/insight/fusion-pharmaceuticals-shareholders-approve-acquisition-by-astrazeneca-5523182)
- 2024-05-29 20:05 UTC [Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca](https://www.quantisnow.com/insight/fusion-pharmaceuticals-shareholders-approve-acquisition-by-astrazeneca-5523049)
- 2024-05-10 20:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-fusion-pharmaceuticals-inc-5481960)
- 2024-05-10 11:54 UTC [SEC Form 8-K] [SEC Form 8-K filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-fusion-pharmaceuticals-inc-5480134)
- 2024-05-09 21:28 UTC [Market Chatter] [Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/fusion-pharmaceuticals-announces-first-patient-dosed-in-the-phase-2-5479103)
- 2024-05-09 20:14 UTC [Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/fusion-pharmaceuticals-announces-first-patient-dosed-in-the-phase-2-5477801)
- 2024-05-07 12:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Fusion Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-fusion-pharmaceuticals-inc-5465028)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/FUSN
- Earnings history: https://www.quantisnow.com/earnings/FUSN
- Dividend history: https://www.quantisnow.com/dividends/FUSN
- Insider transactions: https://www.quantisnow.com/insiders/FUSN
- Options chain: https://www.quantisnow.com/options/FUSN
- SEC 8-K filings only: https://www.quantisnow.com/company/FUSN/8-k
- RSS and alerts for FUSN: https://www.quantisnow.com/docs/rss-feeds.md